3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Daratumumab is a human monoclonal antibody targeting CD38, an antigen uniformly expressed by plasma cells in multiple myeloma and light-chain amyloidosis (AL). We report the results of a prospective multicenter phase 2 study of daratumumab monotherapy in AL (NCT02816476). Forty previously treated AL patients with a difference between involved and uninvolved free light chains (dFLC) >50 mg/L were included in 15 centers between September of 2016 and April of 2018. Patients received 6 28-day cycles of IV daratumumab, every week for cycles 1 and 2 and every 2 weeks for cycles 3 through 6. Median age was 69 years (range, 45-83). Twenty-six patients had ≥2 organs involved, with heart in 24 and kidney in 26. Median time from diagnosis to enrollment was 23 months (interquartile range, 4-122), with a median of 3 prior therapies (range, 1-5). At data cutoff (September of 2019), all patients discontinued therapy; 33 received the planned 6 cycles. Overall, 22 patients had hematological response, and 19 patients (47.5%) achieved very good partial response (dFLC <40 mg/L) or better. Median time to hematological response was 1 week. Patients with no response after 4 doses were unlikely to respond further. Renal and cardiac responses occurred in 8 and 7 patients, respectively. Daratumumab was well tolerated, with no unexpected adverse events. With a median follow-up of 26 months, the 2-year overall survival rate was 74% (95% confidence interval, 62-81). Daratumumab monotherapy is associated with deep and rapid hematological responses in previously treated AL patients, with a good safety profile. Further studies of daratumumab in combination regimens are warranted.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: not found

          Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

          Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1-2 trial involving patients with relapsed myeloma or relapsed myeloma that was refractory to two or more prior lines of therapy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.

            Daratumumab targets CD38-expressing myeloma cells through a variety of immune-mediated mechanisms (complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis) and direct apoptosis with crosslinking. These mechanisms may also target nonplasma cells that express CD38, which prompted evaluation of daratumumab's effects on CD38-positive immune subpopulations. Peripheral blood (PB) and bone marrow (BM) from patients with relapsed/refractory myeloma from 2 daratumumab monotherapy studies were analyzed before and during therapy and at relapse. Regulatory B cells and myeloid-derived suppressor cells, previously shown to express CD38, were evaluated for immunosuppressive activity and daratumumab sensitivity in the myeloma setting. A novel subpopulation of regulatory T cells (Tregs) expressing CD38 was identified. These Tregs were more immunosuppressive in vitro than CD38-negative Tregs and were reduced in daratumumab-treated patients. In parallel, daratumumab induced robust increases in helper and cytotoxic T-cell absolute counts. In PB and BM, daratumumab induced significant increases in CD8(+):CD4(+) and CD8(+):Treg ratios, and increased memory T cells while decreasing naïve T cells. The majority of patients demonstrated these broad T-cell changes, although patients with a partial response or better showed greater maximum effector and helper T-cell increases, elevated antiviral and alloreactive functional responses, and significantly greater increases in T-cell clonality as measured by T-cell receptor (TCR) sequencing. Increased TCR clonality positively correlated with increased CD8(+) PB T-cell counts. Depletion of CD38(+) immunosuppressive cells, which is associated with an increase in T-helper cells, cytotoxic T cells, T-cell functional response, and TCR clonality, represents possible additional mechanisms of action for daratumumab and deserves further exploration.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

              Daratumumab (DARA) is a human CD38-specific IgG1 antibody that is in clinical development for the treatment of multiple myeloma (MM). The potential for IgG1 antibodies to induce macrophage-mediated phagocytosis, in combination with the known presence of macrophages in the tumor microenvironment in MM and other hematological tumors, led us to investigate the contribution of antibody-dependent, macrophage-mediated phagocytosis to DARA's mechanism of action. Live cell imaging revealed that DARA efficiently induced macrophage-mediated phagocytosis, in which individual macrophages rapidly and sequentially engulfed multiple tumor cells. DARA-dependent phagocytosis by mouse and human macrophages was also observed in an in vitro flow cytometry assay, using a range of MM and Burkitt's lymphoma cell lines. Phagocytosis contributed to DARA's anti-tumor activity in vivo, in both a subcutaneous and an intravenous leukemic xenograft mouse model. Finally, DARA was shown to induce macrophage-mediated phagocytosis of MM cells isolated from 11 of 12 MM patients that showed variable levels of CD38 expression. In summary, we demonstrate that phagocytosis is a fast, potent and clinically relevant mechanism of action that may contribute to the therapeutic activity of DARA in multiple myeloma and potentially other hematological tumors.
                Bookmark

                Author and article information

                Contributors
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                Journal
                Blood
                American Society of Hematology
                0006-4971
                1528-0020
                April 30 2020
                April 30 2020
                : 135
                : 18
                : 1531-1540
                Affiliations
                [1 ]Hématologie Clinique, IUC Oncopole, Toulouse, France;
                [2 ]Amyloidosis Research and Treatment Center, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy;
                [3 ]Department of Molecular Medicine, University of Pavia, Pavia, Italy;
                [4 ]U1153 Centre de Recherche en Épidémiologie et Statistiques (CRESS), Equipe de Recherche en Biostatistiques et Epidémiologie Clinique (ECSTRRA),
                [5 ]Service d'Immuno-Hématologie Clinique, Hôpital Saint Louis, Assistance Publique–Hôpitaux de Paris (AP–HP), Université de Paris, Paris, France;
                [6 ]Service d’Hématologie, Institut Paoli Calmette, Marseille, France;
                [7 ]Service d’Hématologie Clinique, Centre Hospitalier Universitaire (CHU) Nancy, Nancy, France;
                [8 ]Service d’Hématologie, Hôpital Sud, CHU Lyon, Lyon, France;
                [9 ]Service Néphrologie et Transplantation d’Organes, Hôpital Rangueil, CHU Toulouse, Toulouse, France;
                [10 ]Institut d'Hématologie de Basse-Normandie, CHU Caen, Caen, France;
                [11 ]Service Hématologie Clinique et Thérapies Cellulaires, CHU Amiens, Amiens, France;
                [12 ]Service d’Hématologie Adultes Hôpital Necker, AP–HP Paris, Paris, France;
                [13 ]Service d’Hématologie, CHU Nantes, Nantes, France;
                [14 ]Service des Maladies du Sang, Centre Hospitalier Régional Universitaire (CHRU) Lille, Lille, France;
                [15 ]Service d’Hématologie, CH Metz, France;
                [16 ]Unité Hémopathies Lymphoïdes, Hôpital Henri-Mondor, AP–HP Créteil, Créteil, France;
                [17 ]Centre de Référence pour l'Amylose AL et autres Maladies de Dépôts d'Immunoglobulines Monoclonales and
                [18 ]Service d’Hématologie Clinique et de Thérapie Cellulaire, CHU Limoges, Limoges, France; and
                [19 ]Service de Néphrologie, Hémodialyse et Transplantation Rénale, Centre d'Investigation Clinique (CIC) INSERM 1402, CHU Poitiers, Poitiers, France
                Article
                10.1182/blood.2019004369
                32108228
                b5e8f6c8-b8f2-40ca-b4cc-3d78b2965dc1
                © 2020
                History

                Comments

                Comment on this article